The most commonly referenced dose of GHRP-6 in clinical and off-label settings is 100 micrograms (mcg) per injection, administered subcutaneously two to three times per day. That number appears across multiple human studies and retrospective clinical reviews, but there is no universally approved dosing guideline because GHRP-6 has never received regulatory approval as a pharmaceutical drug in major markets. What researchers have established is that GHRP-6’s growth hormone release is dose-dependent and that its short half-life shapes how often it needs to be administered to sustain elevated growth hormone output.
How GHRP-6 Triggers Growth Hormone Release
GHRP-6 was the first synthetic peptide shown to specifically trigger growth hormone release in a dose-dependent fashion, both in isolated cells and in living organisms.1PubMed Central. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects The peptide was originally derived from modifications of enkephalin molecules, and by 1981, researchers had identified that it released growth hormone through a pathway distinct from the body’s own growth hormone-releasing hormone (GHRH).2PubMed. Small molecule mimetics of GHRP-6 This distinction matters for dosing because the two pathways can be activated at the same time, producing effects that are greater than either one alone.
At the cellular level, GHRP-6 triggers a two-phase calcium response in the pituitary cells that produce growth hormone. A brief exposure causes a quick spike in intracellular calcium followed by sustained oscillations, and this response scales with concentration across a very wide range.3PubMed. GHRP-6 induces a biphasic calcium response in rat pituitary somatotrophs In practical terms, this means that more GHRP-6 generally produces more growth hormone, up to a ceiling. That dose-response curve is what researchers have used to identify the range where you get meaningful growth hormone release without diminishing returns or excessive side effects.
The 100 Mcg Benchmark and How It Emerged
Multiple human studies have used 100 mcg as a standard intravenous or subcutaneous bolus dose. In research on the combined effects of GHRP-6 and GHRH, an intravenous bolus of 100 mcg of each peptide was administered to patients with type 2 diabetes, producing measurable growth hormone peaks.4Diabetes Research and Clinical Practice. Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp A retrospective review of 105 men on testosterone therapy who were also prescribed GHRP-6 used 100 mcg three times daily, and this protocol raised serum IGF-1 levels meaningfully.5PubMed Central. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels The thrice-daily schedule reflects the peptide’s pharmacokinetics: GHRP-6 is cleared from the body quickly, so a single daily injection would leave most of the day without elevated growth hormone stimulation.
Some users in non-clinical settings experiment with doses ranging from roughly 50 mcg to 300 mcg per injection, but the bulk of the published human evidence clusters around the 100 mcg figure. Going higher doesn’t necessarily produce proportionally more growth hormone because the pituitary has a limited pool of stored growth hormone that can be released at any one time. Exceeding a certain threshold can also amplify unwanted hormonal effects, which we’ll get to shortly.
Why the Peptide’s Short Half-Life Dictates Frequency
A pharmacokinetic study in nine healthy men measured how GHRP-6 behaves in the body after injection. The peptide distributes quickly, with a distribution half-life of about 7.6 minutes, and is eliminated with a half-life of roughly 2.5 hours.6European Journal of Pharmaceutical Sciences. Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers That means the peptide hits peak blood levels within minutes of injection, triggers a pulse of growth hormone, and is mostly gone within a few hours. This is why protocols call for two or three daily injections spaced several hours apart rather than a single larger dose. A once-daily injection would create one growth hormone pulse in the morning and leave the rest of the day unstimulated.
The timing of those injections also matters. Many practitioners suggest dosing on an empty stomach or at least avoiding high-carbohydrate meals close to injection, for reasons tied to how blood sugar interacts with the growth hormone response.
Blood Sugar and the Blunted Response
High blood sugar reduces how much growth hormone GHRP-6 can release. In a controlled study of men with type 2 diabetes, the growth hormone peak after GHRP-6 plus GHRH was about 25% lower during a high-sugar condition compared to a normal-sugar condition, and the total growth hormone output over time dropped by a similar margin.7Diabetes Research and Clinical Practice. Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp This is not a trivial reduction. If you eat a large meal rich in carbohydrates and then inject GHRP-6 an hour later, you may be spending the same amount of peptide for a weaker growth hormone pulse.
This finding also has broader implications for people with insulin resistance or poorly managed diabetes. Their baseline blood sugar is chronically elevated, which could mean that GHRP-6 works less effectively for them across the board. Animal research reinforces this link: the metabolic effects of GHRP-6 on weight gain and fat accumulation appear to depend on insulin and glucose status, with the peptide’s effects on fat storage being amplified when insulin is present and functioning normally.8Endocrinology. The Positive Effects of Growth Hormone-Releasing Peptide-6 on Weight Gain and Fat Mass Accrual Depend on the Insulin/Glucose Status In plain terms, GHRP-6 doesn’t operate in a vacuum. Your metabolic state modulates the output you get from a given dose.
The Synergy with GHRH
One of the most striking findings in the GHRP-6 literature is that combining it with GHRH produces a growth hormone response far larger than you’d expect by simply adding the two individual responses together. In healthy subjects, growth hormone output after GHRH alone averaged about 484 units, after GHRP-6 alone about 1,435 units, but after both together, it reached roughly 3,772 units. That combined figure was statistically higher than the sum of the individual values, meaning the interaction is genuinely synergistic rather than just additive.9The Journal of Clinical Endocrinology & Metabolism. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection
This synergy has been replicated across multiple populations. In one study of control subjects, the growth hormone output after GHRH plus GHRP-6 was more than three times higher than after GHRP-6 alone and more than five times higher than after GHRH alone.10PubMed. Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing’s syndrome Even in obese subjects, who typically have blunted growth hormone responses, the combination of GHRP-6 and GHRH produced what researchers described as a “massive discharge” of growth hormone, with individual peaks ranging from 14 to 86 mcg/L.11The Journal of Clinical Endocrinology & Metabolism. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6
This is why some protocols pair GHRP-6 with a GHRH analog like modified GRF (1-29). The rationale is that you can keep the GHRP-6 dose moderate while getting a disproportionately larger growth hormone pulse from the combination. However, the synergy also means the combined protocol carries amplified hormonal effects, including on cortisol and appetite, so more isn’t automatically better.
The Hunger Problem
One of the most immediately noticeable effects of GHRP-6, even at standard doses, is a sharp increase in appetite. This isn’t a subtle nudge toward snacking. Many users describe intense hunger within 15 to 30 minutes of injection, sometimes difficult to ignore. The mechanism is tied to the same receptor that ghrelin, the body’s natural “hunger hormone,” acts on. GHRP-6 mimics ghrelin’s activity, stimulating feeding behavior and activating appetite-related brain regions. In animal studies, both ghrelin and GHRP-6 increased food intake through a pathway involving NPY receptors in the brain, and blocking those receptors prevented the feeding response.12Endocrinology. Acute Central Ghrelin and GH Secretagogues Induce Feeding and Activate Brain Appetite Centers
For someone trying to gain muscle mass, the appetite boost might be welcome. For someone using GHRP-6 primarily for fat loss or anti-aging purposes, it can be counterproductive. This appetite effect is one of the main reasons people switch from GHRP-6 to newer peptides that stimulate growth hormone with less hunger. GHRP-6 also accelerates gastric emptying and gut transit by activating nerve pathways in the gut wall, which may contribute to the speed and intensity of the hunger sensation.13European Journal of Pharmacology. Comparison of the gastroprokinetic effects of ghrelin, GHRP-6 and motilin in rats in vivo and in vitro
Hormonal Effects Beyond Growth Hormone
GHRP-6 does not exclusively affect growth hormone. It also stimulates the release of ACTH, cortisol, and to a lesser degree prolactin. In a study administering GHRP-6 to healthy men, the growth hormone concentration nearly tripled compared to placebo, but ACTH levels also rose and cortisol secretion roughly doubled during the first half of the night.14Neuroendocrinology. Growth Hormone-Releasing Peptide-6 Stimulates Sleep, Growth Hormone, ACTH and Cortisol Release in Normal Man Related synthetic peptides like GHRP-2 and hexarelin show a similar pattern of raising prolactin, ACTH, and cortisol alongside growth hormone, confirming this is a class-wide characteristic rather than something unique to GHRP-6.15PubMed. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH
The cortisol increase is worth paying attention to. Cortisol is a stress hormone that, when chronically elevated, can break down muscle tissue, increase fat storage around the midsection, and impair immune function. At standard doses and with intermittent use, the cortisol bump from GHRP-6 appears transient. But in protocols involving higher doses or chronic daily use over many months, the cumulative cortisol exposure is a legitimate concern. The prolactin elevation is generally mild but could become relevant for men over extended use, since elevated prolactin can reduce libido and affect sexual function.
How GHRP-6 Compares to Newer Peptides
GHRP-6 was the first in its class, but it has since been joined by several analogs that were designed to improve on its profile. Ipamorelin, for instance, has similar potency and efficacy to GHRP-6 in releasing growth hormone. In head-to-head comparisons across different animal models, the two peptides required similar doses to produce similar growth hormone peaks.16European Journal of Endocrinology. Ipamorelin, the first selective growth hormone secretagogue The key difference is selectivity: ipamorelin was described as the first “selective” growth hormone secretagogue because it releases growth hormone without the same degree of cortisol, ACTH, or prolactin stimulation that GHRP-6 causes. For someone whose primary goal is clean growth hormone elevation with fewer off-target hormonal effects, ipamorelin has become a more popular choice.
GHRP-2, another close relative, is generally considered more potent on a per-microgram basis but shares GHRP-6’s tendency to raise cortisol and prolactin.17PubMed. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH In animal models, GHRP-2 showed higher potency but lower maximum efficacy compared to both GHRP-6 and ipamorelin, meaning it hits a lower ceiling of total growth hormone output even though it gets there at a smaller dose.18European Journal of Endocrinology. Ipamorelin, the first selective growth hormone secretagogue Hexarelin is the most potent of the group but also the most likely to cause desensitization with repeated use, which is why it fell out of favor for ongoing protocols.
All of these peptides operate through in vivo potencies in the same general ballpark, with effective doses in animal models clustering around low single-digit nanomoles per kilogram of body weight.19PubMed. A new series of highly potent growth hormone-releasing peptides derived from ipamorelin What separates them for practical purposes is their side-effect profile, not their ability to release growth hormone per se.
Tissue-Protective Effects and the CD36 Receptor
Beyond its role in stimulating growth hormone, GHRP-6 binds to a second receptor called CD36, which is found on heart cells, blood vessel walls, and immune cells. Activation of this receptor triggers cellular survival pathways that can reduce cell death, an effect that is independent of growth hormone release entirely.20PubMed Central. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects This has led to a separate line of research exploring GHRP-6 as a potential cardioprotective or tissue-protective agent, particularly in contexts like heart attack or organ damage where cells are dying from lack of blood flow.
Animal research has also explored GHRP-6 for anti-inflammatory and anti-fibrotic applications, including models of acute lung injury where the peptide was administered after an inflammatory insult and appeared to reduce progression toward scarring and fibrosis. The doses used in these animal studies vary widely from the standard growth-hormone-stimulating protocols in humans, and this line of research remains preclinical. Still, it suggests that the optimal dose of GHRP-6 might look very different depending on whether the goal is growth hormone release or tissue protection, since the two effects act through different receptors.
Muscle Differentiation and Modified GHRP-6 Compounds
Researchers have also experimented with chemically modified versions of GHRP-6 to see if the peptide’s effects on muscle can be enhanced. A GHRP-6-biotin conjugate was shown to stimulate muscle cell differentiation and increase the expression of IGF-1 and collagen type I, both of which are involved in muscle growth and connective tissue integrity.21PubMed Central. Growth hormone-releasing peptide-biotin conjugate stimulates myocytes differentiation through insulin-like growth factor-1 and collagen type I This is still laboratory-stage work using cell cultures rather than human subjects, but it points toward a future where modified versions of the peptide could be tailored for specific tissues rather than triggering a broad systemic growth hormone pulse.
The gap between cell-culture findings and practical human dosing is enormous, and these modified compounds are not currently available outside of research settings. But the work illustrates why GHRP-6 continues to attract scientific interest decades after its discovery: the peptide’s interactions with multiple receptor systems give it a range of potential applications that extend well beyond the growth hormone axis. For the person primarily interested in growth hormone stimulation, 100 mcg two to three times daily on an empty stomach remains the most commonly referenced human protocol, ideally paired with a GHRH analog to take advantage of the synergistic effect and keep individual peptide doses moderate.
Metabolic Complications in Animal Models
Not all of GHRP-6’s metabolic effects are straightforward or desirable. While the peptide promotes fat gain when insulin is functioning normally, the picture gets complicated in diabetic states. In insulin-deficient diabetic rats, GHRP-6 alone did not improve weight loss, blood sugar, or the disrupted appetite-regulating signals in the brain. Only when insulin was restored did GHRP-6 amplify weight gain and fat accumulation, particularly in visceral fat depots.22Endocrinology. The Positive Effects of Growth Hormone-Releasing Peptide-6 on Weight Gain and Fat Mass Accrual Depend on the Insulin/Glucose Status Separately, blocking the ghrelin receptor with a GHRP-6-based antagonist in diabetic mice unexpectedly worsened glucose and insulin tolerance and appeared to directly inhibit insulin secretion.23PubMed Central. Long-term treatment with the ghrelin receptor antagonist [d-Lys3]-GHRP-6 does not improve glucose homeostasis in nonobese diabetic MKR mice
These animal findings don’t translate directly to healthy humans using GHRP-6 at standard doses, but they serve as a caution that the ghrelin-receptor system is deeply intertwined with insulin signaling and glucose management. For anyone with pre-existing insulin resistance or diabetes, the interaction between GHRP-6 and metabolic health is not simple enough to assume that more growth hormone automatically means better outcomes. The peptide’s effects on body composition are context-dependent in ways that basic dosing recommendations do not capture.